Candel Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Candel Therapeutics to Present at Upcoming Investor Conferences

   GlobeNewswire MAY 6, 2025 8:05 AM EDT
   NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company...
   READ ARTICLE

2. Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

   GlobeNewswire APR 23, 2025 4:05 PM EDT
   NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Compa...
   READ ARTICLE

3. Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

   GlobeNewswire APR 1, 2025 8:01 AM EDT
   NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Compa...
   READ ARTICLE

4. Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

   GlobeNewswire MAR 26, 2025 4:05 PM EDT
   Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 ...
   READ ARTICLE

5. Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

   GlobeNewswire MAR 20, 2025 8:00 AM EDT
   NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Compa...
   READ ARTICLE

6. Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

   GlobeNewswire MAR 18, 2025 8:00 AM EDT
   NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Compa...
   READ ARTICLE

7. Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

   GlobeNewswire MAR 13, 2025 4:15 PM EDT
   Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical tri...
   READ ARTICLE

8. Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

   GlobeNewswire FEB 25, 2025 8:00 AM EST
   Positive final survival data after additional follow-up showed notable improvement in estimated m...
   READ ARTICLE

9. Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

   GlobeNewswire JAN 13, 2025 8:00 AM EST
   On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pa...
   READ ARTICLE

10. Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    GlobeNewswire DEC 16, 2024 4:01 PM EST
    NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candelȁ...
    READ ARTICLE